News

aHUS is a severe and life-threatening ultra-rare disorder that affects around 200 people in England, with 20-30 new patients diagnosed with the condition each year. The disease causes

The results show that Immunoca® with statistical significance imparts a performance benefit of approximately 10 per cent in muscle strength. This is very relevant for healthy aging, as

CareNet provides solutions to several large pharma companies in Japan. CareNet offers MRPlus, a service that delivers pharmaceutical information online to physicians; e-research, an online pharmaceutical research service;

The newly issued patents are assigned to VIVUS and will be submitted for listing in the FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) and

PACF partners with local organisations working to improve the health and wellbeing of women and children affected by HIV, and the communities they live in. All PACF projects

The move is claimed to be the first time in North America that people have been treated with the narcotic after being part of a clinical research trial,

Recipharm will significantly expand its pharmaceutical development capacity and technical capabilities to provide easier access for development services to its French and other customers. Recipharm will also provide

Vargatef in combination with docetaxel is approved for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology,

At present, Dynavax has global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications. As part of the deal, Dynavax carried out